Compare Goldman Sachs Group Inc (GS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs Novo Nordisk A/S — how do they compare? Goldman Sachs Group Inc trades at $895.32 (market cap $256.98B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Goldman Sachs Group Inc is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Goldman Sachs Group Inc for 101 Days and Novo Nordisk A/S for 116 Days on average.
| GS | NVO | |
|---|---|---|
Market Cap | $256.98B | $165.31B |
Volume | 1,748,426 | 11,432,838 |
Sector | Financials | Health |
52-Week High | $1.15K | $63.98 |
52-Week Low | $744.60 | $35.29 |
Typical Hold Time | 101 Days | 116 Days |
Enterprise Value | $814.98B | $179.56B |
Dividend Yield | 2.27% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $882.59, down 0.52% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company shows strong profitability with a 31.68% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights CEO David Solomon's focus on expanding earnings and building a durable revenue base, while the FICC business is expected to soften in Q3 2026.
The stock presents a mixed outlook: attractive valuation with a P/E of 13.63 and consensus price target of $1,130 suggests upside, but negative operating cash flows and high debt levels pose risks. Analyst sentiment is cautious with 40% buy ratings, while institutional interest remains steady. Key catalysts include revenue growth in asset and wealth management, but macroeconomic volatility and competitive pressures could hinder performance.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
